JENKINS
WILSON
&TAYLOR
patent attorneys

June 25, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 25, 2004.

Patty Wilson
Date of Signature: June 25, 2004

RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
GREGORY A. HUNT
E. ERIC MILLS
BENTLEY J. OLIVE
MICHAEL J. CROWLEY
*CHRIS PERKINS, PH.D.
**JAMES DALY IV, PH.D.
JEFFREY CHILDERS, PH.D.
OF COUNSEL
SOROJINI BISWAS
*LICENSED ONLY IN CA
**LICENSED ONLY IN KY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/806,899 for
A DIAGNOSTIC METHOD FOR EPILEPSY
Our Ref. No. 1386/19

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages) in duplicate;
3. Copies of cited references (10 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. **50-0426**.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw
Enclosures
Customer No: 25297

tel 919.493.8000
fax 919.419.0383
Jenkins, Wilson & Taylor, P.A.
JenkinsWilsonTaylor.com
University Tower, Suite 1400 | 3100 Tower Boulevard | Durham, North Carolina 27707

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petrou et al.

Group Art Unit: To be Assigned

Serial No.: 10/806,899

Examiner: To be Assigned

Filed: March 23, 2004

Docket No.: 1386/19

For: A DIAGNOSTIC METHOD FOR EPILEPSY

* * * * * * * * * * * * *

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

No fee under 37 C.F.R. Section 1.17(p) is due as the undersigned hereby certifies that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months

prior to the filing of this statement.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. **50-0426**.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 06/25/2004

By: _____

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Attorney Docket No.: 1386/19	Serial No.: 10/806,899
	Applicant(s): Petrou et al.	
	Filing Date: March 23, 2004	Group:

U.S. PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes | No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1.	International Search Report for PCT/AU2004/000295 dated May 14, 2004.
	2.	Examiner's First Report for Australian Patent Application No. 2004200978 dated May 6, 2004.
	3.	Cannon, *Sodium Channel Gating: No Margin for Error*, Neuron **34**:853-858 (June 13, 2002).
	4.	Fujiwara et al., *Mutations of sodium channel α subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures*, Brain **126**:531-546 (2003).
	5.	Lerche et al., *Ion Channels and Epilepsy*, Am. J. of Med. Genetics **106**:146-159 (2001).
	6.	Madia et al., *No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy*, Epilepsy Research **53**:196-200 (2003).
	7.	Malacarne et al., *Lack of SCN1A Mutations in Familial Febrile Seizures*, Epelepsia **43(5)**:559-562 (2002).
	8.	Ohmori, et al., *Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy*, Biochemical and Biophysical Research Communications **295**:17-23 (2002).

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Attorney Docket No.: 1386/19	Serial No.: 10/806,899
	Applicant(s): Petrou et al.	
	Filing Date: March 23, 2004	Group:

	9.	Spampanato et al., *Generalized Epilepsy with Febrile Seizures Plus Type 2 Mutation W1204R Alters voltage-Dependent Gating of $Na_v1.1$ Sodium Channels*, Neuroscience **116**:37-48 (2003).
	10.	Sugawara et al., *Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy*, Neurology **58**:1122-1124 (2002).

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.